Obiettivo
The oncogenic fusion protein BCR/ABL causes human leukemia. A specific inhibitor of BCR/ABL is an effective treatment of tumors in vivo. The project aims at investigating molecular mechanisms underlying resistance to the inhibitor in vivo.
Campo scientifico
Argomento(i)
Invito a presentare proposte
Data not availableMeccanismo di finanziamento
RGI - Research grants (individual fellowships)Coordinatore
20133 MILANO
Italia